Trial Information

Summary: Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Phase II Study Protocol

You have/your child has been asked to participate in this research study because you are/your child is suffering from a life-threatening fungal infection which is known to be or is suspected to be mucormycosis.  The purpose of this study is to determine the safety and tolerability of AmBisome (standard antifungal treatment) plus deferasirox (experimental antifungal treatment) or placebo (inactive substance).  The study will also look at the effectiveness of the two treatments.  The study will also evaluate how much deferasirox stays in the body over time and the relationship to the amount of iron and of immunosuppressive medications (given to prevent rejection after transplant) in the body.  Your/your child's participation in this study is expected to last up to 14 days for treatment and up to 80 days for follow up (90-95 days total).

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: December 1, 2008 at 3:15:49 PM